HC Wainwright & Co. : Indaptus Therapeutics (INDP.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
Zhitong FinanceApr 15 18:11
Indaptus Therapeutics Analyst Ratings
BenzingaApr 15 18:06
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
BenzingaApr 15 18:08
Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough With Decoy20 Platform
TipRanksApr 13 03:05
Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlook
TipRanksMar 15 01:55
Buy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 With Promising Developments
TipRanksMar 7 03:15
Analysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)
TipRanksNov 7, 2023 22:50
Indaptus Therapeutics: Promising Phase 1 Results and Optimistic Valuation Bolster Buy Rating
TipRanksNov 3, 2023 18:39
Maxim Group Remains a Buy on Indaptus Therapeutics (INDP)
TipRanksSep 21, 2023 02:55
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
BenzingaSep 20, 2023 18:32
Indaptus Therapeutics Analyst Ratings
BenzingaSep 20, 2023 18:32
Analysts' Top Healthcare Picks: Indaptus Therapeutics (INDP), Achieve Life Sciences (ACHV)
TipRanksAug 15, 2023 23:30
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
BenzingaAug 15, 2023 18:55
Indaptus Therapeutics Analyst Ratings
BenzingaAug 15, 2023 18:55
H.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)
TipRanksAug 15, 2023 18:35
Maxim Group Remains a Buy on Indaptus Therapeutics (INDP)
TipRanksAug 11, 2023 23:25
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
BenzingaAug 11, 2023 19:14
Indaptus Therapeutics Analyst Ratings
BenzingaAug 11, 2023 19:13
Indaptus Therapeutics (INDP) Receives a Buy From H.C. Wainwright
TipRanksAug 8, 2023 18:25
Indaptus Therapeutics Analyst Ratings
BenzingaAug 8, 2023 18:19
No Data
No Data